JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

The Journal of Nuclear Medicine Vol. 33 No. 3 325-329
© 1992 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Okada, J.
Right arrow Articles by Arimizu, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Okada, J.
Right arrow Articles by Arimizu, N.

Positron Emission Tomography using Fluorine-18-Fluorodeoxyglucose in Malignant Lymphoma: A Comparison with Proliferative Activity

Junichi Okada, Kyosan Yoshikawa, Makiko Itami, Keiko Imaseki, Kimiichi Uno, Jun Itami, Junpei Kuyama, Atsuo Mikata and Noboru Arimizu

Departments of Radiology and Pathology, University of Chiba School of Medicine, 1-8-1 Inohana, Chiba City, Chiba, Japan

Correspondence: For reprints contact: Junichi Okada, MD, Department of Radiology, University of Chiba School of Medicine, 1-8-1 Inohana, Chiba City, Chiba, 280 Japan.

ABSTRACT

To evaluate the relationship between PET using 18F-fluoro-deoxyglucose (FDG) and pathological findings and to compare indices obtained by FOG-PET, FDG-PET was performed in 23 patients with untreated malignant lymphoma. Three indices obtained by FDG-PET, tumor-to-normal contrast ratio (TCR), distribution absorption ratio (OAR), k1k2/(k2+ k3), correlated with proliferative activity which was pathologically estimated both by mitotic count and by proportion of cells in all phases of the cell cycle. The relationship did not significantly change according to which of the three indices was chosen. FDG-PET, which shows the proliferative activity of tumors, is considered to be a useful method for managing tumors.




This article has been cited by other articles:


Home page
 JNMHome page
J.-L. Roh, C. H. Ryu, S.-H. Choi, J. S. Kim, J. H. Lee, K.-J. Cho, S. Y. Nam, and S. Y. Kim
Clinical Utility of 18F-FDG PET for Patients with Salivary Gland Malignancies
J. Nucl. Med., February 1, 2007; 48(2): 240 - 246.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
E. Y. Tsai, A. Taur, L. Espinosa, A. Quon, D. Johnson, S. Dick, S. Chow, R. Advani, R. Warnke, S. Kohler, et al.
Staging accuracy in mycosis fungoides and sezary syndrome using integrated positron emission tomography and computed tomography.
Arch Dermatol, May 1, 2006; 142(5): 577 - 584.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. E. Juweid and B. D. Cheson
Role of Positron Emission Tomography in Lymphoma
J. Clin. Oncol., July 20, 2005; 23(21): 4577 - 4580.
[Full Text] [PDF]

Home page
 The OncologistHome page
J. W. Friedberg and V. Chengazi
PET Scans in the Staging of Lymphoma: Current Status
Oncologist, October 1, 2003; 8(5): 438 - 447.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
H. Schoder, J. Meta, C. Yap, M. Ariannejad, J. Rao, M. E. Phelps, P. E. Valk, J. Sayre, and J. Czernin
Effect of Whole-Body 18F-FDG PET Imaging on Clinical Staging and Management of Patients with Malignant Lymphoma
J. Nucl. Med., August 1, 2001; 42(8): 1139 - 1143.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
A. C. Buck, H. H. Schirrmeister, C.-A. Guhlmann, C. G. Diederichs, C. Shen, I. Buchmann, J. Kotzerke, D. Birk, T. Mattfeldt, and S. N. Reske
Ki-67 Immunostaining in Pancreatic Cancer and Chronic Active Pancreatitis: Does In Vivo FDG Uptake Correlate with Proliferative Activity?
J. Nucl. Med., May 1, 2001; 42(5): 721 - 725.
[Abstract] [Full Text]

Home page
 JNMHome page
M. Tatsumi, H. Kitayama, H. Sugahara, N. Tokita, H. Nakamura, Y. Kanakura, and T. Nishimura
Whole-Body Hybrid PET with 18F-FDG in the Staging of Non-Hodgkin's Lymphoma
J. Nucl. Med., April 1, 2001; 42(4): 601 - 608.
[Abstract] [Full Text]

Home page
 JNMHome page
N. Avril, M. Menzel, J. Dose, M. Schelling, W. Weber, F. Janicke, W. Nathrath, and M. Schwaiger
Glucose Metabolism of Breast Cancer Assessed by 18F-FDG PET: Histologic and Immunohistochemical Tissue Analysis
J. Nucl. Med., January 1, 2001; 42(1): 9 - 16.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Vesselle, R. A. Schmidt, J. M. Pugsley, M. Li, S. G. Kohlmyer, E. Vallières, and D. E. Wood
Lung Cancer Proliferation Correlates with [F-18]Fluorodeoxyglucose Uptake by Positron Emission Tomography
Clin. Cancer Res., October 1, 2000; 6(10): 3837 - 3844.
[Abstract] [Full Text]

Home page
 BloodHome page
R. Carr, S. F. Barrington, B. Madan, M. J. O'Doherty, C. A.B. Saunders, J. van der Walt, and A. R. Timothy
Detection of Lymphoma in Bone Marrow by Whole-Body Positron Emission Tomography
Blood, May 1, 1998; 91(9): 3340 - 3346.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
F. G. Duhaylongsod, V. J. Lowe, E. F. Patz Jr, A. L. Vaughn, R. E. Coleman, and W. G. Wolfe
Lung Tumor Growth Correlates With Glucose Metabolism Measured by Fluoride-18 Fluorodeoxyglucose Positron Emission Tomography
Ann. Thorac. Surg., November 1, 1995; 60(5): 1348 - 1352.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1992 by the Society of Nuclear Medicine.